BRPI0905725A2 - vacina, embalagem farmacêutica e processo para criar uma resposta imune em tecido de indivíduo - Google Patents
vacina, embalagem farmacêutica e processo para criar uma resposta imune em tecido de indivíduoInfo
- Publication number
- BRPI0905725A2 BRPI0905725A2 BRPI0905725A BRPI0905725A BRPI0905725A2 BR PI0905725 A2 BRPI0905725 A2 BR PI0905725A2 BR PI0905725 A BRPI0905725 A BR PI0905725A BR PI0905725 A BRPI0905725 A BR PI0905725A BR PI0905725 A2 BRPI0905725 A2 BR PI0905725A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- create
- immune response
- pharmaceutical packaging
- individual tissue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2057308P | 2008-01-11 | 2008-01-11 | |
US61/020,573 | 2008-01-11 | ||
PCT/US2009/030754 WO2009089535A2 (en) | 2008-01-11 | 2009-01-12 | Polypeptide vaccine and vaccination strategy against mycobacterium |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0905725A2 true BRPI0905725A2 (pt) | 2015-12-01 |
BRPI0905725B1 BRPI0905725B1 (pt) | 2020-12-29 |
BRPI0905725B8 BRPI0905725B8 (pt) | 2021-05-25 |
Family
ID=40853787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0905725A BRPI0905725B8 (pt) | 2008-01-11 | 2009-01-12 | vacina e embalagem farmacêutica |
Country Status (6)
Country | Link |
---|---|
US (1) | US8741313B2 (pt) |
EP (2) | EP2818178A1 (pt) |
CN (1) | CN101969976A (pt) |
BR (1) | BRPI0905725B8 (pt) |
WO (1) | WO2009089535A2 (pt) |
ZA (1) | ZA201005742B (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
CN101822829B (zh) * | 2010-04-07 | 2013-07-31 | 四川大学 | 一种用于结核病预防的重组卡介苗 |
CN101850111B (zh) * | 2010-04-07 | 2013-07-31 | 四川大学 | 一种用于结核病预防的新型疫苗 |
SI2661253T1 (sl) | 2011-01-04 | 2017-07-31 | Archivel Farma, Sl | Liposomska formulacija, ustrezna za zdravljenje ali preprečevanje tuberkuloze |
EP2471511A1 (en) * | 2011-01-04 | 2012-07-04 | Archivel Farma, SL | Liposome formulation suitable for treating or preventing tuberculosis |
BR112014017217B1 (pt) | 2012-01-12 | 2023-01-17 | Archivel Farma, S.L | Agente e composição farmacêutica |
BR102012003790A2 (pt) * | 2012-02-17 | 2014-04-22 | Fundacao Butantan | Cepa de mycobacterium recombinante, composição imunogênica e uso |
RU2539026C1 (ru) * | 2013-06-11 | 2015-01-10 | Федеральное государственное бюджетное учреждение "Центральный научно-исследовательский институт туберкулеза" Российской академии медицинских наук | РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-CFP10-DBD, РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15 [pREP4, pESAT6-CFP10-DBD], СПОСОБ ПОЛУЧЕНИЯ, ИММОБИЛИЗАЦИИ, КОНЦЕНТРИРОВАНИЯ И ОЧИСТКИ РЕКОМБИНАНТНОГО БЕЛКА ESAT6-CFP10-DBD НА ДЕКСТРАНЕ, РЕКОМБИНАНТНЫЙ БЕЛОК ESAT6-CFP10-DBD И ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК ESAT6-CFP10-DBD |
US10414819B2 (en) | 2013-08-30 | 2019-09-17 | Longhorn Vaccines And Diagnostics, Llc | Monoclonal antibodies that modulate immunity to MTB and enhance immune clearance |
US10370437B2 (en) | 2013-08-30 | 2019-08-06 | Longhorn Vaccines And Diagnostics, Llc | Antibodies that modulate immunity to drug resistant and latent MTB infections |
WO2015031787A2 (en) * | 2013-08-30 | 2015-03-05 | Longhorn Vaccines And Diagnostics, Llc | Enhancing immunity to tuberculosis |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
MX2019003035A (es) * | 2016-09-16 | 2019-09-13 | Infectious Disease Res Inst | Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra. |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
WO2018236876A2 (en) * | 2017-06-19 | 2018-12-27 | Washington University | NANOEMULSIONS AND METHODS OF USE THEREOF |
CN111655281A (zh) * | 2018-01-26 | 2020-09-11 | 加利福尼亚大学董事会 | 用于结核病的含环二核苷酸佐剂的疫苗的鼻内递送 |
CN112770771A (zh) * | 2018-09-17 | 2021-05-07 | 丘拉提斯股份有限公司 | 包含干扰素基因刺激蛋白激动剂的免疫佐剂及疫苗组合物 |
KR102317403B1 (ko) * | 2019-01-28 | 2021-10-29 | 주식회사 바이오앱 | 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법 |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
CN110240637A (zh) * | 2019-06-04 | 2019-09-17 | 华中农业大学 | 牛分枝杆菌免疫相关的分子伴侣蛋白GroEL2及其编码基因与应用 |
CN110354098B (zh) * | 2019-07-23 | 2021-01-05 | 中国农业大学 | 重组蛋白cfp-10纳米颗粒的制备及应用 |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
WO2022066926A1 (en) * | 2020-09-23 | 2022-03-31 | The General Hospital Corporation | Bcg vaccinations for prevention of covid-19 and other infectious diseases |
CN114404582B (zh) * | 2021-12-20 | 2023-08-11 | 南京鼓楼医院 | 通过分枝杆菌特异性免疫治疗肿瘤的方法及使用的抗原肽 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196191A (en) | 1975-09-29 | 1980-04-01 | Burroughs Wellcome Co. | Biological preparations |
GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
US6096291A (en) | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
US7037510B2 (en) * | 1997-04-18 | 2006-05-02 | Statens Serum Institut | Hybrids of M. tuberculosis antigens |
US6979456B1 (en) | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
DE69912441T2 (de) | 1998-08-19 | 2004-08-19 | Skyepharma Canada Inc., Verdun | Injizierbare wässerige propofoldispersionen |
US6630169B1 (en) * | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
AU2001257359A1 (en) | 2000-04-27 | 2001-11-07 | Verion Inc. | Zero order release and temperature-controlled microcapsules and process for the preparation thereof |
US6368602B1 (en) | 2000-06-16 | 2002-04-09 | Hadasit Medical Research Services And Development Ltd | Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine |
AU2001271963A1 (en) * | 2000-07-10 | 2002-01-21 | Colorado State University Research Foundation | Mid-life vaccine and methods for boosting anti-mycobacterial immunity |
CA2423484A1 (en) | 2000-09-27 | 2002-04-04 | Verion Inc. | Instant water dissolvable encapsulate and process |
US6663861B2 (en) | 2000-11-09 | 2003-12-16 | Antibodyshop A/S | Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins |
FR2818647B1 (fr) * | 2000-12-21 | 2006-09-29 | Pasteur Institut | Glycopeptides immunogenes, criblage, preparation et applications |
CA2435637A1 (en) | 2001-01-23 | 2002-08-01 | Massachusetts Institute Of Technology | Solid- and solution -phase synthesis of heparin and other glycosaminoglycans |
CN1277843C (zh) * | 2001-02-22 | 2006-10-04 | 巴斯德研究院 | 分枝杆菌比较基因组学作为鉴定分枝杆菌病的诊断、预防或治疗靶的工具 |
AU2001271554B2 (en) * | 2001-06-21 | 2009-03-12 | New York University | Mycobacterial proteins as early antigens for serodiagnosis and vaccines |
CN1694725A (zh) * | 2001-08-02 | 2005-11-09 | 纽约大学 | 肽在早期检测分枝杆菌疾病中的应用 |
US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
US20050075298A1 (en) * | 2002-01-31 | 2005-04-07 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
AU2003242504A1 (en) * | 2002-07-13 | 2004-02-02 | Statens Serum Institut | Therapeutic tuberculosis vaccines |
CA2523084C (en) * | 2003-04-23 | 2012-09-04 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Tuberculosis vaccine with improved efficacy |
GB0323965D0 (en) | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
WO2005061534A2 (en) * | 2003-12-23 | 2005-07-07 | Statens Serum Institut | Improved tuberculosis vaccines |
EP1649869A1 (en) | 2004-10-21 | 2006-04-26 | Vakzine Projekt Management GmbH | Combination of a recombinant mycobacterium and a biologically active agent as a vaccine |
KR100609813B1 (ko) | 2005-02-24 | 2006-08-08 | 학교법인연세대학교 | 결핵 예방 백신 |
CN102836425B (zh) * | 2005-06-23 | 2015-08-19 | 国家血清研究中心 | 包含潜伏感染阶段期间所表达的抗原的结核疫苗 |
-
2009
- 2009-01-12 CN CN2009801088394A patent/CN101969976A/zh active Pending
- 2009-01-12 US US12/812,541 patent/US8741313B2/en active Active
- 2009-01-12 BR BRPI0905725A patent/BRPI0905725B8/pt active IP Right Grant
- 2009-01-12 EP EP14176196.5A patent/EP2818178A1/en not_active Ceased
- 2009-01-12 WO PCT/US2009/030754 patent/WO2009089535A2/en active Application Filing
- 2009-01-12 EP EP09700748A patent/EP2244720A4/en not_active Withdrawn
-
2010
- 2010-08-11 ZA ZA2010/05742A patent/ZA201005742B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US8741313B2 (en) | 2014-06-03 |
BRPI0905725B1 (pt) | 2020-12-29 |
EP2244720A2 (en) | 2010-11-03 |
EP2244720A4 (en) | 2013-01-16 |
EP2818178A1 (en) | 2014-12-31 |
ZA201005742B (en) | 2011-04-28 |
BRPI0905725B8 (pt) | 2021-05-25 |
US20110027349A1 (en) | 2011-02-03 |
WO2009089535A3 (en) | 2009-10-01 |
CN101969976A (zh) | 2011-02-09 |
WO2009089535A2 (en) | 2009-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0905725A2 (pt) | vacina, embalagem farmacêutica e processo para criar uma resposta imune em tecido de indivíduo | |
BR112012019757A2 (pt) | composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular | |
BRPI0914493A2 (pt) | transportador e método para girar um artigo | |
BRPI1011404A2 (pt) | mutantes e usos dos mesmos | |
BRPI0918261A2 (pt) | processos e sistema de processamento de dados para controlar peso corporal, bem como processo e sistema de processamento de dados para selecionar um produto alimentício com base no efeito do produto alimentício sobre a saúde de um ser humano | |
EP2694660A4 (en) | EFFICIENT IN VIVO PROTEIN EXPRESSION USING MODIFIED RNA (MOD RNA) | |
BRPI0920283A2 (pt) | composição e método para induzir resposta imunológica humoral | |
BRPI0920282A2 (pt) | composição e método para induzir resposta imunológica humoral | |
IT1392423B1 (it) | Struttura di guanto, in particolare da motociclismo, e metodo per la sua realizzazione. | |
BR112012001172A2 (pt) | artigo, e, método | |
FI20085760A0 (fi) | Muunnettu komposiittituote ja menetelmä sen valmistamiseksi | |
BRPI0921951A2 (pt) | embalagem para produtos de tabaco e modelo | |
BRPI0818477A2 (pt) | Dc-sign, icam-3 e lsectin porcinos e usos dos mesmos | |
BRPI1009840A2 (pt) | Base saborosa realçadora de sabor natural e processo para sua preparação | |
DK3785730T3 (da) | Aluminiumforbindelser til anvendelse i terapeutiske produkter og vacciner | |
BR112012026848A2 (pt) | suplemento alimentar ou medicinal e método para induzir saciedade em um indivíduo | |
BR112013024402A2 (pt) | processo para produtos terapêuticos encapsulados e usos dos mesmos | |
BRPI0919789A2 (pt) | metodo para identificar peptídeos e proteínas alergênicas | |
BRPI0922190A2 (pt) | Ácidos insaturados para proteção do desbotamento das cores provenientes de fontes naturais utilizadas em produtos de bebida | |
FR2953520B1 (fr) | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique | |
BRPI1010086A2 (pt) | método e produtos para tratamento de doenças | |
FI20090142A0 (fi) | Uudet menetelmät ja tuotteet | |
BRPI1007721A2 (pt) | composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduo | |
BRPI0919485A2 (pt) | vacinas, antígenos, composições de plasmodium e métodos | |
BRPI1007294A2 (pt) | Método para melhorar a função imune em um animal, e, composição |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |